---
schema_version: "secwatch.filing_event.v1"
accession: "0001159036-25-000061"
form_type: "8-K"
ticker: "HALO"
cik: "0001159036"
company_name: "HALOZYME THERAPEUTICS, INC."
filed_at: "2025-11-24T23:59:59+00:00"
generated_at: "2026-05-16T17:15:39.187182+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.45
calibrated_materiality_score: 0.45
confidence: "high"
source: SEC EDGAR
---

# Halozyme CFO Nicole LaBrosse to depart by March 30, 2026 under transition agreement

## Summary
- CFO Nicole LaBrosse will remain until new CFO is hired or March 30, 2026, whichever comes first.
- Transition agreement provides 120% target bonus for 2025, severance equal to base salary plus pro-rated 2026 bonus.
- Equity awards vesting through February 28, 2026 will accelerate; option exercise period extended to one year post-separation.
- If a Change in Control occurs within one year after separation, unvested options will fully vest.
- COBRA coverage premiums paid for one year; agreement filed with 2025 10-K.

## SEC filing metadata
- accession: 0001159036-25-000061
- form_type: 8-K
- ticker: HALO
- cik: 0001159036
- company_name: HALOZYME THERAPEUTICS, INC.
- filed_at: 2025-11-24T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.45
- calibrated_materiality_score: 0.45
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1159036/000115903625000061/0001159036-25-000061-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1159036/000115903625000061/halo-20251118.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001159036-25-000061
- JSON: https://secwatch.observer/filing/0001159036-25-000061.json
- Plain text: https://secwatch.observer/filing/0001159036-25-000061.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.